双酰基单环β-内酰胺衍生物的体外抗肿瘤活性研究
Biacyl Substituted Monocycle β-LactamDerivative for Evaluation as Anticancer Agents
DOI: 10.12677/WJCR.2019.91005, PDF,   
作者: 高海涛：湖北医药学院药学院，湖北 十堰；曾小华*：湖北省武当特色中药研究重点实验室及湖北医药学院医学化学研究所，湖北 十堰
关键词: 双酰基取代单环β-内酰胺；体外抗肿瘤活性研究；Diacyl Substituted β-Lactam； Antitumor
摘要: 目的：研究双酰基取代单环β-内酰胺类化合物对脑胶质瘤细胞(U87)、宫颈癌细胞(HeLa)、肝癌细胞(HepG2)3种肿瘤细胞和1种正常细胞间充质干细胞(MSC)的体外抗肿瘤活性。方法：采用MTT法测定了不同药物浓度对细胞的抑制作用，以半数抑制浓度(IC50)评价目标化合物的抗肿瘤活性。结果：实验结果表明双酰基取代单环β-内酰胺对U87、HeLa、HepG2和MSC正常细胞都具有一定的抑制作用，其中，化合物5a对HepG2细胞增殖的抑制活性最强，其IC50值为8.15 μmol/L。结论：初步的体外抗肿瘤活性测试显示双酰基取代单环β-内酰胺类化合物具有抑制肿瘤细胞的生长，表现出潜在的抗肿瘤活性。
Abstract: Objective: To study antitumor activities of diacyl substituted monocyclic β-Lactam derivatives against U87, HeLa and HepG2 human tumor cell lines and MSC human normal cell lines. Method: The antitumor activities of diacyl substituted monocyclic β-Lactam derivatives were screened using cis-platinum as positive contron by MTT method. Results: Among them 5a stood out as the most po-tent showing an IC50 of 8.15 μmol/L against human tumor cell lines (HepG2). Conclusion: Bioassay of the compounds indicated that diacyl substituted monocyclic β-Lactam derivatives showed potential antitumor activities, which these compounds can be established as lead molecules for developing novel antitumor drugs.
文章引用：高海涛, 曾小华. 双酰基单环β-内酰胺衍生物的体外抗肿瘤活性研究[J]. 世界肿瘤研究, 2019, 9(1): 27-31. https://doi.org/10.12677/WJCR.2019.91005

参考文献

[1] Chow, E., Cushing-Haugen, K.L., Cheng, G.-S., Boeckh, M., Khera, N., Lee, S.J., Leisenring, W.M., Martin, P.J., Mueller, B.A., Schwartz, S.M. and Baker, K.S. (2017) Morbidity and Mortality Differences between Hematopoietic Cell Transplantation Survivors and Other Cancer Survivors. Journal of Clinical Oncology, 35, 306-313.
[Google Scholar] [CrossRef] 
[2] Devlin, E.J., Denson, L.A. and Whitford, H.S. (2017) Cancer Treatment Side Effects: Ameta-Analysis of the Relationship between Response Expectancies and Experience. Journal of Pain and Symptom Man-agement, 54, 245-258.
[Google Scholar] [CrossRef] [PubMed]
[3] Martins, P., Jesus, J., Santos, S., Raposo, L.R., Roma-Rodrigues, C., Baptista, P.V. and Fernandes, A.R. (2015) Heterocyclic Anticancer Compounds: Recent Advances and the Paradigm Shift towards the Use of Nanomedicine’s Tool Box. Molecules, 20, 16852-16891.
[Google Scholar] [CrossRef] [PubMed]
[4] Zhou, P., Liu, Y., Zhou, L., Zhu, K., Feng, K., Zhang, H., Liang, Y., Jiang, H., Luo, C., Liu, M. and Wang, Y. (2016) Potent Antitumor Activities and Structure Basis of the Chiral β-Lactam Bridged Analogue of Combretastatin A-4 Binding to Tubulin. Journal of Medicinal Chemistry, 59, 10329-10334.
[Google Scholar] [CrossRef] [PubMed]
[5] Finke, P.E., Shah, S.K., Fletcher, D.S., Ashe, B.M., Brause, K.A., Chandler, G.O., Dellea, P.S., Hand, K.M., Maycock, A.L., Osinga, D.G., Underwood, D.J., Weston, H., Davies, P. and Doherty, J.B. (1995) Orally Active. β-Lactaminhibitors of Human Leukocyte Elastase. 3. Stereospecific Synthesis and Structure-Activity Relationships for 3, 3-Dialkylazetidin-2-ones. Journal of Medicinal Chemistry, 38, 2449-2462.
[Google Scholar] [CrossRef] [PubMed]
[6] Buynak, J.D., Rao, A.S., Fod, G.P., Carver, C., Carver, C., Adam, G., Geng, B., Bachmann, B., Shobassy, S. and Lackey, S. (1997) 7-Alkylidenecephalosporin Esters as Inhibitors of Human Leukocyte Elastase. Journal of Medicinal Chemistry, 40, 3423-3433.
[Google Scholar] [CrossRef] [PubMed]
[7] Wu, G.G. (2000) A Concise Asym-metric Synthesis of a β-Lactam-Based Cholesterol Absorption Inhibitor. Organic Process Research & Development, 4, 298-300.
[Google Scholar] [CrossRef] 
[8] O’Boyle, N.M., Greene, L.M., Bergin, O., Fichet, J.B., McCabe, T., Lloyd, D.G., Zis-terer, D.M. and Meegan, M.J. (2011) Synthesis, Evaluation and Structural Studies of Antiproliferative Tubulin-Targeting Azet-idin-2-Ones. Bioorganic & Medicinal Chemistry, 19, 2306-2325.
[Google Scholar] [CrossRef] [PubMed]
[9] Carr, M., Knox, A.J.S., Lloyd, D.G., Zisterer, D.M. and Meegan, M.J. (2016) Development of the -Lactam Type Molecular Scaffold for Selective Estrogen Receptor Modulator Action: Synthesis and Cytotoxic Effects in MCF-7 Breast Cancer Cells. Journal of Enzyme Inhibition and Medicinal Chemistry, 31, 117-130.
[Google Scholar] [CrossRef] [PubMed]
[10] Xing, B., Rao, J. and Liu, R. (2008) Novel Beta-Lactam Antibiotics Derivatives: Their New Applications as Gene Reporters, Antitumor Prodrugs and Enzyme Inhibitors. Mini-Reviews in Medicinal Chemistry, 8, 455-471.
[11] Nuzzi, A., Fiasella, A., Ortega, J.A., Pagliuca, C., Ponzano, S., Pizzirani, D., Bertozzi, S.M., Ottonello, G., Tarozzo, G., Reggiani, A., Bandiera, T., Bertozzi, F. and Piomelli, D. (2016) Potent α-Amino-β-Lactam Carbamic Acid Ester as NAAA Inhibitors. Synthesis and Structure-Activity Relationship (SAR) Studies. European Journal of Medicinal Chemistry, 111, 138-159.
[Google Scholar] [CrossRef] [PubMed]
[12] Zeng, X.-H., Wang, H.-M., Yan, Y.-M. and Ding, M.-W. (2014) One-Pot Regioselective Synthesis of β-Lactams by a Tandem Ugi 4CC/SN Cyclization. Tetrahedron, 70, 3647-3652.
[Google Scholar] [CrossRef] 

为你推荐